Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement
18 1월 2023 - 9:00PM
Genetron Holdings Limited ("Genetron Health" or the "Company",
NASDAQ: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today announced that the Company had received a notification letter
(“Compliance Notice”) from the staff of the Listing Qualifications
Department of the Nasdaq Stock Market LLC (“Nasdaq”),
dated January 17, 2023, indicating that the Company has
regained compliance with the minimum bid price requirement set
forth under the Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid
Price Requirement”).
As previously announced, the Company was
notified by Nasdaq on October 28, 2022 that the Company
was not in compliance with the Minimum Bid Price Requirement as the
bid price of the Company’s American depositary shares (“ADSs”)
closed below US$1.00 per share for 30 consecutive
business days.
On January 17, 2023, Nasdaq confirmed in
the Compliance Notice that for the ten consecutive business days,
from December 29, 2022 to January 13, 2023, the closing bid
price of the Company’s ADSs has been at US$1.00 per share
or greater. Accordingly, the Company has regained compliance with
Listing Rule 5450(a)(1), and the matter is closed.
About Genetron Holdings
Limited
Genetron Holdings Limited ("Genetron Health" or
the "Company") (Nasdaq: GTH) is a leading precision oncology
platform company in China that specializes in cancer molecular
profiling and harnesses advanced technologies in molecular biology
and data science to transform cancer treatment. The Company has
developed a comprehensive oncology portfolio that covers the entire
spectrum of cancer management, addressing needs and challenges from
early screening, diagnosis and treatment recommendations, as well
as continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking
statements made under the "safe harbor" provisions of Section 21E
of the Securities Exchange Act of 1934, as amended, and the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
“will,” “expects,” “anticipates,” “future,” “intends,” “plans,”
“believes,” “estimates” and similar statements. Genetron Health may
also make written or oral forward-looking statements in its
periodic reports to the SEC, in its annual report to shareholders,
in press releases and other written materials and in oral
statements made by its officers, directors or employees to third
parties. Statements that are not historical facts, including
statements about Genetron Health’s beliefs and expectations, are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties. A number of factors could cause
actual results to differ materially from those contained in any
forward-looking statement, including but not limited to the
following: impact of the COVID-19 pandemic, Genetron Health’s goal
and strategies; its future business development, financial
condition and results of operations; Genetron Health’s expectations
regarding demand for, and market acceptance of, its services; the
laws and regulations relating to Genetron Health’s industry; the
general economic and business conditions; and assumptions
underlying or related to any of the foregoing. Further information
regarding these and other risks is included in Genetron Health’s
filings with the SEC. All information provided in this announcement
and in the attachments is as of the date of this press release, and
Genetron Health does not undertake any obligation to update any
forward-looking statement, except as required under applicable
law.
Investor Relations
ContactEmail: ir@genetronhealth.com
Genetron (NASDAQ:GTH)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Genetron (NASDAQ:GTH)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024